ClinicalTrials.govpublic full text
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
refractory chronic lymphocytic leukemia, cll, monoclonal antibody therapy, anti cd20, biologic response modifier therapy, fractionated-dose, low-dose, chronic lymphocytic leukemia, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 811687
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.